ACE and COVID-19: Lastly, we assessed immune cell surface expression of the activation marker, ACE (21), which may be a contributing factor to COVID-19 outcomes (29) and immunotherapeutic responses (30) in patients requiring antihypertensive treatment (e.g., ACE inhibition).